Surrozen, Inc. (SRZN)Healthcare | Biotechnology | South San Francisco, United States | NasdaqCM
31.56 USD
+1.24
(4.090%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 31.50 -0.06 (-0.060%) ⇩ (April 17, 2026, 5:55 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 10:26 p.m. EDT
Despite a short-term rebound and positive analyst revisions, SRZN faces an existential long-term cease-of-operations risk; the negative revenue growth, negative book value, and cash burn signal a high-probability non-performing scenario that warrants avoidance despite the short-term speculative bounce. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.167451 |
| MSTL | 0.324477 |
| AutoETS | 0.335192 |
| AutoARIMA | 0.338952 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.60 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.475 |
| Excess Kurtosis | -0.88 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.465 |
| Market Cap | 371,227,904 |
| Forward P/E | -8.85 |
| Beta | 0.52 |
| Previous Name | Consonance-HFW Acquisition Corp. |
| Website | https://www.surrozen.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 2.2875 |
| Address1 | 171 Oyster Point Boulevard |
| Address2 | Suite 400 |
| All Time High | 210.0 |
| All Time Low | 4.5 |
| Ask | 31.99 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 157,490 |
| Average Daily Volume3 Month | 117,717 |
| Average Volume | 117,717 |
| Average Volume10Days | 157,490 |
| Beta | 0.517 |
| Bid | 30.76 |
| Bid Size | 1 |
| Book Value | -19.209 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 31.56 |
| Current Ratio | 9.22 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 31.7 |
| Day Low | 29.65 |
| Display Name | Surrozen |
| Earnings Timestamp End | 1,746,821,116 |
| Earnings Timestamp Start | 1,746,821,116 |
| Ebitda | -41,555,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -6.736 |
| Enterprise To Revenue | 80.505 |
| Enterprise Value | 279,914,464 |
| Eps Current Year | -3.7 |
| Eps Forward | -3.565 |
| Eps Trailing Twelve Months | -32.37 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 26.7632 |
| Fifty Day Average Change | 4.7967987 |
| Fifty Day Average Change Percent | 0.17923114 |
| Fifty Two Week Change Percent | 228.74998 |
| Fifty Two Week High | 33.22 |
| Fifty Two Week High Change | -1.6600018 |
| Fifty Two Week High Change Percent | -0.04996995 |
| Fifty Two Week Low | 5.9 |
| Fifty Two Week Low Change | 25.66 |
| Fifty Two Week Low Change Percent | 4.3491526 |
| Fifty Two Week Range | 5.9 - 33.22 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,610,375,400,000 |
| Float Shares | 5,421,151 |
| Forward Eps | -3.565 |
| Forward P E | -8.852735 |
| Free Cashflow | -16,856,500 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 44 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -25,888,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03089 |
| Held Percent Institutions | 0.94444 |
| Implied Shares Outstanding | 11,762,608 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-08-12 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,702,512,000 |
| Last Split Factor | 1:15 |
| Long Business Summary | Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs' endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California. |
| Long Name | Surrozen, Inc. |
| Market | us_market |
| Market Cap | 371,227,904 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_401948183 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-04-19 |
| Net Income To Common | -242,026,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 363,669,143 |
| Number Of Analyst Opinions | 4 |
| Open | 30.3 |
| Operating Cashflow | -30,244,000 |
| Operating Margins | -23.9375 |
| Payout Ratio | 0.0 |
| Phone | 650 489 9000 |
| Post Market Change | -0.059999466 |
| Post Market Change Percent | -0.19011238 |
| Post Market Price | 31.5 |
| Post Market Time | 1,776,462,945 |
| Prev Name | Consonance-HFW Acquisition Corp. |
| Previous Close | 30.32 |
| Price Eps Current Year | -8.52973 |
| Price Hint | 2 |
| Price To Book | -1.6429799 |
| Price To Sales Trailing12 Months | 106.76672 |
| Profit Margins | 0.0 |
| Quick Ratio | 9.008 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 1.24 |
| Regular Market Change Percent | 4.08971 |
| Regular Market Day High | 31.7 |
| Regular Market Day Low | 29.65 |
| Regular Market Day Range | 29.65 - 31.7 |
| Regular Market Open | 30.3 |
| Regular Market Previous Close | 30.32 |
| Regular Market Price | 31.56 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 132,721 |
| Return On Assets | -0.35746 |
| Revenue Growth | -0.194 |
| Revenue Per Share | 0.465 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 11,762,608 |
| Shares Percent Shares Out | 0.0301 |
| Shares Short | 345,450 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 288,706 |
| Short Name | Surrozen, Inc. |
| Short Percent Of Float | 0.0552 |
| Short Ratio | 3.73 |
| Source Interval | 15 |
| State | CA |
| Symbol | SRZN |
| Target High Price | 42.0 |
| Target Low Price | 36.0 |
| Target Mean Price | 38.75 |
| Target Median Price | 38.5 |
| Total Cash | 89,245,000 |
| Total Cash Per Share | 7.769 |
| Total Debt | 6,639,000 |
| Total Revenue | 3,477,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -32.37 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 17.532925 |
| Two Hundred Day Average Change | 14.027075 |
| Two Hundred Day Average Change Percent | 0.8000419 |
| Type Disp | Equity |
| Volume | 132,721 |
| Website | https://www.surrozen.com |
| Zip | 94,080 |